Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once ...

Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, M42, a global health champion powered by AI, technology and genomics and PureHealth, the largest healthcare group in the Middle ...

Panelists discuss how spinal muscular atrophy is an autosomal recessive genetic disease affecting motor neurons with 3 ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...

Children suffering from Spinal Muscular Atrophy (SMA) – a rare but debilitating genetic condition – are being denied a simple ...

The Syrian girl suffers from spinal muscular atrophy, a rare and serious genetic disorder that affects muscle strength and ...

The baby from Ranaghat in Nadia is suffering from spinal muscular atrophy (SMA) Type I, a condition that causes progressive weakening of the muscles and nerves ...

BiogenBIIB said Wednesday its experimental treatment helped children with a devastating muscle-wasting disease even after they received an approved gene therapy from NovartisNVS.The company already ...

New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.

Baby Aasmika with SMA Type 1 received Zolgensma, the world’s most expensive gene therapy, thanks to India's largest-ever ...